Citigroup Inc Annexon, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Annexon, Inc. stock. As of the latest transaction made, Citigroup Inc holds 669,158 shares of ANNX stock, worth $4.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

669,158

Previous 12,879 5095.73%

Holding current value

$4.84 Million

Previous $92,000 3463.04%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$4.33 - $6.79 $2.84 Million - $4.46 Million	656,279 Added 5095.73%	669,158 $3.28 Million
Q1 2024 May 10, 2024	BUY	$4.03 - $7.81 $23,474 - $45,493	5,825 Added 82.58%	12,879 $92,000
Q4 2023 Feb 09, 2024	BUY	$1.63 - $4.63 $9,690 - $27,525	5,945 Added 536.07%	7,054 $32,000
Q3 2023 Nov 09, 2023	SELL	$2.13 - $3.84 $29,411 - $53,022	-13,808 Reduced 92.57%	1,109 $2,000
Q2 2023 Aug 10, 2023	SELL	$2.1 - $6.37 $143,129 - $434,160	-68,157 Reduced 82.04%	14,917 $52,000
Q1 2023 May 11, 2023	BUY	$3.74 - $7.46 $9,593 - $19,134	2,565 Added 3.19%	83,074 $319,000
Q4 2022 Feb 09, 2023	BUY	$4.56 - $6.61 $348,475 - $505,136	76,420 Added 1868.92%	80,509 $416,000
Q3 2022 Nov 10, 2022	BUY	$3.75 - $6.63 $10,338 - $18,278	2,757 Added 206.98%	4,089 $26,000
Q2 2022 Aug 10, 2022	SELL	$2.11 - $4.06 $19,042 - $36,641	-9,025 Reduced 87.14%	1,332 $5,000
Q1 2022 May 12, 2022	SELL	$2.73 - $11.94 $145,940 - $638,288	-53,458 Reduced 83.77%	10,357 $28,000
Q4 2021 Feb 10, 2022	BUY	$11.49 - $22.0 $636,419 - $1.22 Million	55,389 Added 657.36%	63,815 $733,000
Q3 2021 Nov 10, 2021	BUY	$16.35 - $23.4 $137,765 - $197,168	8,426 New	8,426 $157,000

Others Institutions Holding ANNX

# of Institutions

157

Shares Held

101M

Call Options Held

3.61M

Put Options Held

1.08M

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $344M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account